UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from _________ to ________ Commission file number 001-40791 2seventy bio, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3658454 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the quarterly period ended March 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from _________ to ________ Commission file number 001-40791 2seventy bio, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3658454 (State or other juri ...

2seventy bio, Inc. (NASDAQ:TSVT) Q1 2023 Earnings Call Transcript May 3, 2023 4:30 PM ET Company Participants Jenn Snyder - SVP of Corporate Affairs Nick Leschly - President, CEO & Director Philip Gregory - Chief Scientific Officer Steven Bernstein - Chief Medical Officer William Baird - CFO Conference Call Participants Daina Graybosch - SVB Securities LLC Operator Good day, and thank you for standing by. Welcome to the 2seventy bio First Quarter 2023 Financial Results Conference Call. (Operator Instruction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40791 2seventy bio, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3658454 (State or other jurisdiction of (I.R. ...

| --- | --- | |------------------------------------------------|-------| | | | | | | | | | | | | | | | | Unleash Time 2seventy bio company presentation | | | January 2023 | | | | | Cautionary note regarding forward-looking statements 2 These slides and the accompanying oral presentation may contain "forward-looking statements". These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development, manufacture or sale of our produ ...